Skip to content
Open access

Survival and Extent of Breast Surgery in Patients with Complete Response After Neoadjuvant Therapy: A Retrospective Analysis from the EUSOMA Database

Nov 2026 · Cancers · 0 citations

TL;DR

In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy, and these findings support BCS as a safe treatment option for this patient population.

Abstract

Background: Optimal management of breast cancer (BC) patients with pathological complete response (pCR) after neoadjuvant therapy (NAT) remains debated. We performed a retrospective analysis to evaluate whether the extent of surgery influences survival outcomes in this patient population. Methods: Using the EUSOMA database, we retrospectively collected data of women with pCR after NAT, excluding those with BRCA1/2 mutations. The cohort was stratified by surgery type, i.e., breast-conserving surgery (BCS) or mastectomy. Relapse-free survival (RFS) and overall survival (OS) were compared using Cox regression. Results: Of 467 patients, 327 (70.0%) underwent BCS and 140 (30.0%) underwent mastectomy. Women treated with mastectomy were more likely to have multifocal tumors and advanced disease. After a median follow-up of 5.6 years, 7.3% of patients experienced BC recurrence. Axillary nodal involvement (cN+) and mastectomy were independently associated with recurrence, occurring in 11.4% of cN+ compared to 3.7% of cN0 patients (HR 3.02; 95% CI: 1.40–6.51; p = 0.005) and in 12.5% of mastectomy vs. 5.2% of BCS patients (HR 2.08; 95% CI: 1.05–4.11; p 0.035). cN+ patients also showed significantly higher mortality rates (9.4% vs. 1.6% of cN0; HR 6.16; 95%CI: 2.09–18.17; p= 0.001). However, surgery type did not impact OS. Conclusion: In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy. Baseline nodal involvement independently predicted recurrence and mortality; however, the type of surgery did not impact OS. These findings support BCS as a safe treatment option for this patient population.

Read PDF

Similar papers

Open access Oct 2026

Impact of Neoadjuvant Chemotherapy on Pathological Outcomes and Survival in Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Analysis

Neoadjuvant chemotherapy (NAC) is recommended for patients with muscle-invasive bladder cancer (MIBC); however, its impact on survival outcomes remains controversial in real-world clinical settings. This retrospective observational study evaluated the effect of NAC on pathological outcomes and overall survival among pa...

I. Topcu, Bulut Dural, Ömer Faruk Yıldırım et al. · 0 citations
Open access Oct 2026

Residual DCIS Versus No Residual Breast Tumor After Neoadjuvant Chemotherapy in ypN0 Breast Cancer: A Retrospective Clinical, MRI, and Survival Comparison

Background/Objectives: The prognostic significance of residual ductal carcinoma in situ (ypTis) compared with no residual tumor in the breast (ypT0) after neoadjuvant chemotherapy (NAC) remains uncertain. We compared clinicopathological, MRI, treatment, and survival outcomes between these groups. Methods: This single-c...

O. Mermut, Berrin Yalcın, R. Gürsu et al. · 0 citations
Review Open access Oct 2026

Clinicopathological Factors Associated with Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study

Objective: This study aimed to determine the pathological complete response (pCR) rate and evaluate clinicopathological factors associated with pCR in patients with breast cancer who underwent surgery after neoadjuvant chemotherapy (NAC).Materials and Methods: We retrospectively reviewed 53 women who received NAC follo...

Mehmet Ali Karatutlu, B. Ocak · 0 citations
Open access 2026

Do surgical techniques influence survival in early breast cancer? A retrospective cohort study of 1,517 patients in Brazil

Introduction: Surgical choice in breast cancer (extent of oncologic resection and use of reconstruction) is primarily guided by oncologic safety and patient preference. Prognosis is mainly driven by tumor biology and stage, but perceived survival differences across surgical techniques persist. Objective: To compare su...

N. Almeida, N. S. de Azevedo, F. Brenelli et al. · 0 citations
Open access Oct 2026

Outcomes of Upfront Surgery Versus Neoadjuvant Therapy-Preceded Surgery in Patients of Luminal A Breast Cancer with Axillary Nodal Involvement, A Prospective Comparative Study

Neoadjuvant chemotherapy has a beneficial effect on nodal status of luminal A EBC patients; constituting for skipping the formal axillary lymph node dissection (ALND) and it does not reduce the breast and axillary post-operative complications to significant values.

Mennat Allah M.Y, Abo Elqassem, M. Ahmed et al. · 0 citations
Open access 2026

Oncologic outcomes of breast-conserving surgery following neoadjuvant versus adjuvant chemotherapy: a brazilian multicenter cohort study

Introduction: Neoadjuvant chemotherapy (NAC) is a cornerstone in breast cancer treatment, particularly for locally advanced, triple-negative, and human epidermal growth factor receptor 2 (HER2)-positive disease. However, concerns remain regarding the oncologic safety of breast-conserving surgery (BCS) following NAC com...

A. D. Nascimento Lima, A. Matter, F. Cavalcante et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.